logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Celgene Quanticel Research, Inc.


USPTO Granted Patents = 106



Forward Citations = 176

Loading Chart...
Loading Chart...

44 inventors (with patents filed for the assignee):

goldMedal Jeffrey Alan Stafford (76 out of 141 patents)

silverMedal James Marvin Veal (72 out of 104 patents)

bronzeMedal Toufike Kanouni (57 out of 85 patents)

4.  Young K Chen (55 out of 63 patents)

5.  Michael Brennan Wallace (52 out of 94 patents)

6.  Zhe Nie (31 out of 47 patents)

7.  Amogh Boloor (27 out of 33 patents)

8.  Stephen W Kaldor (18 out of 66 patents)

9.  Robert Cho (8 out of 9 patents)

10.  Juan Manuel Betancort (7 out of 19 patents)

11.  Aaron Nguyen (4 out of 10 patents)

12.  Michael John Bennett (4 out of 11 patents)

13.  Matthew Michael Kreilein (4 out of 18 patents)

14.  Jiangchun Xu (4 out of 55 patents)

15.  Paula Alessandra Tavares-Greco (4 out of 9 patents)


Core Competencies:
Azacitidine
Venetoclax
Gilteritinib
Midostaurin
Histone Demethylase Inhibitors
Bromodomain Inhibitors
Lysine Specific Demethylase-1
Combination Therapy
Solid Tumors
Non-Hodgkin's Lymphomas
Therapeutic Compounds

106 patents:

1. 12447171 - Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome (2025-10-21),
2. 12172998 - Histone demethylase inhibitors (2024-12-24),
3. 11987560 - Inhibitors of lysine specific demethylase-1 (2024-05-21),
4. 11890275 - Therapeutic compounds (2024-02-06),
5. 11884680 - Bromodomain inhibitors (2024-01-30),
6. 11884648 - Histone demethylase inhibitors (2024-01-30),
7. 11679106 - Bromodomain inhibitor (2023-06-20),
8. 11639333 - Histone demethylase inhibitors (2023-05-02),
9. 11566004 - Process for the preparation of bromodomain inhibitor (2023-01-31),
10. 11535616 - Histone demethylase inhibitors (2022-12-27),
11. 11464771 - Bromodomain and extra-terminal protein inhibitor combination therapy (2022-10-11),
12. 11214542 - Histone demethylase inhibitors (2022-01-04),
13. 11084793 - Inhibitors of lysine specific demethylase-1 (2021-08-10),
14. 11028066 - Inhibitors of lysine specific demethylase-1 (2021-06-08),
15. 11020380 - Therapeutic compounds (2021-06-01),
Celgene Quanticel Research, Inc. is a biotechnology company focused on research and development of innovative therapies for cancer and other diseases. As a subsidiary of Celgene Corporation, Quanticel leverages advanced genomic technologies and bioinformatics to discover and validate targets that may lead to new treatment approaches. The company's mission is to develop precision medicine solutions to improve patient outcomes and quality of life.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

106 Patents

#59 in San Diego, CA

#799 in California

#3,452 in US

#7,173 in the World

...
San Diego, CA, United States of America

Celgene Quanticel Research, Inc.

Forward Citations = 176

44 inventors:

goldMedal Jeffrey Alan Stafford (76 out of 141 patents)

silverMedal James Marvin Veal (72 out of 104 patents)

bronzeMedal Toufike Kanouni (57 out of 85 patents)

4.  Young K Chen (55 out of 63 patents)

5.  Michael Brennan Wallace (52 out of 94 patents)

Please report any incorrect information to support@idiyas.com
Loading…